{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:27:58Z","timestamp":1791350878816,"version":"4.3.1"},"reference-count":252,"publisher":"Zhejiang University Press","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1631\/jzus.b1300106","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T01:49:02Z","timestamp":1389145742000},"page":"16-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prostate cancer: the need for biomarkers and new therapeutic targets"],"prefix":"10.1631","volume":"15","author":[{"given":"Juliana","family":"Felgueiras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Vieira","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Fardilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"issue":"1-2","key":"3567_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mce.2007.02.006","volume":"270","author":"DS Aaronson","year":"2007","unstructured":"Aaronson, D.S., Muller, M., Neves, S.R., et al., 2007. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol. Cell. Endocrinol., 270(1-2):50\u201356. [doi:10.1016\/j.mce.2007.02.006]","journal-title":"Mol. Cell. Endocrinol."},{"issue":"19","key":"3567_CR2","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1101\/gad.819500","volume":"14","author":"C Abate-Shen","year":"2000","unstructured":"Abate-Shen, C., Shen, M.M., 2000. Molecular genetics of prostate cancer. Genes Develop., 14(19):2410\u20132434. [doi:10.1101\/gad.819500]","journal-title":"Genes Develop."},{"issue":"6","key":"3567_CR3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2353\/ajpath.2008.071054","volume":"172","author":"J Abdulghani","year":"2008","unstructured":"Abdulghani, J., Gu, L., Dagvadorj, A., et al., 2008. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol., 172(6):1717\u20131728. [doi:10.2353\/ajpath.2008.071054]","journal-title":"Am. J. Pathol."},{"issue":"6","key":"3567_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1631\/jzus.2006.B0411","volume":"7","author":"MA Alaoui-Jamali","year":"2006","unstructured":"Alaoui-Jamali, M.A., Xu, Y.J., 2006. Proteomic technology for biomarker profiling in cancer: an update. J. Zhejiang Univ.-Sci. B, 7(6):411\u2013420. [doi:10.1631\/jzus.2006.B0411]","journal-title":"J. Zhejiang Univ.-Sci. B"},{"issue":"1","key":"3567_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbrc.2012.09.035","volume":"427","author":"A Al-Azayzih","year":"2012","unstructured":"Al-Azayzih, A., Gao, F., Goc, A., et al., 2012. TGF\u03b21 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK\/SAPK-mediated activation of caspases. Biochem. Biophys. Res. Commun., 427(1):165\u2013170. [doi:10.1016\/j.bbrc.2012.09.035]","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"3567_CR6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s11255-012-0220-2","volume":"44","author":"M Al-Maghrebi","year":"2012","unstructured":"Al-Maghrebi, M., Kehinde, E.O., Anim, J.T., et al., 2012. The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer. Int. Urol. Nephrol., 44(6):1681\u20131689. [doi:10.1007\/s11255-012-0220-2]","journal-title":"Int. Urol. Nephrol."},{"issue":"8","key":"3567_CR7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/pros.21306","volume":"71","author":"CE Almasi","year":"2011","unstructured":"Almasi, C.E., Brasso, K., Iversen, P., et al., 2011. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate, 71(8):899\u2013907. [doi:10.1002\/pros.21306]","journal-title":"Prostate"},{"issue":"3","key":"3567_CR8","first-page":"245","volume":"1","author":"MM Amin","year":"2007","unstructured":"Amin, M.M., Jeyaganth, S., Fahmy, N., et al., 2007. Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can. Urol. Assoc. J., 1(3):245\u2013249.","journal-title":"Can. Urol. Assoc. J."},{"issue":"21","key":"3567_CR9","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMe1102758","volume":"364","author":"ES Antonarakis","year":"2011","unstructured":"Antonarakis, E.S., Eisenberger, M.A., 2011. Expanding treatment options for metastatic prostate cancer. N. Engl. J. Med., 364(21):2055\u20132058. [doi:10.1056\/NEJMe1102758]","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"3567_CR10","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1002\/cncr.27689","volume":"118","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis, E.S., Keizman, D., Zhang, Z., et al., 2012. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer, 118(24):6063\u20136071. [doi:10.1002\/cncr.27689]","journal-title":"Cancer"},{"issue":"12","key":"3567_CR11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5306\/wjco.v2.i12.384","volume":"2","author":"A Azevedo","year":"2011","unstructured":"Azevedo, A., Cunha, V., Teixeira, A.L., et al., 2011. IL-6\/IL-6R as a potential key signaling pathway in prostate cancer development. World J. Clin. Oncol., 2(12):384\u2013396. [doi:10.5306\/wjco.v2.i12.384]","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"3567_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1097-0045(19970401)31:1<61::AID-PROS10>3.0.CO;2-M","volume":"31","author":"ER Barrack","year":"1997","unstructured":"Barrack, E.R., 1997. TGF\u03b2 in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31(1):61\u201370. [doi:10.1002\/(SICI)1097-0045(19970401)31:1<61::AID-PROS10>3.0.CO;2-M]","journal-title":"Prostate"},{"issue":"7","key":"3567_CR13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopha.2011.06.003","volume":"65","author":"V Battisti","year":"2011","unstructured":"Battisti, V., Maders, L.D., Bagatini, M.D., et al., 2011. Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomed. Pharmacother., 65(7):516\u2013524. [doi:10.1016\/j.biopha.2011.06.003]","journal-title":"Biomed. Pharmacother."},{"key":"3567_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4419-0711-0_2","volume-title":"Cancer Genome and Tumor Microenvironment","author":"A Bellacosa","year":"2010","unstructured":"Bellacosa, A., Larue, L., 2010. PI3K\/AKT pathway and the epithelial-mesenchymal transition. In: Thomas-Tikhonenko, A. (Ed.), Cancer Genome and Tumor Microenvironment. Springer, New York, p.11\u201332. [doi:10.1007\/978-1-4419-0711-0_2]"},{"issue":"3","key":"3567_CR15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1389450033491118","volume":"4","author":"D Bello-DeOcampo","year":"2003","unstructured":"Bello-DeOcampo, D., Tindall, D.J., 2003. TGF-\u03b2\/Smad signaling in prostate cancer. Curr. Drug Targets, 4(3):197\u2013207. [doi:10.2174\/1389450033491118]","journal-title":"Curr. Drug Targets"},{"issue":"1-2","key":"3567_CR16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cccn.2004.07.022","volume":"350","author":"S Bernardini","year":"2004","unstructured":"Bernardini, S., Miano, R., Iori, R., et al., 2004. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Clin. Chim. Acta, 350(1-2):181\u2013188. [doi:10.1016\/j.cccn.2004.07.022]","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"3567_CR17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-10-1096","volume":"10","author":"A Bhardwaj","year":"2011","unstructured":"Bhardwaj, A., Singh, S., Srivastava, S.K., et al., 2011. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol. Cancer Ther., 10(5):720\u2013731. [doi:10.1158\/1535-7163.MCT-10-1096]","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"3567_CR18","first-page":"3289","volume":"29","author":"B Bickers","year":"2009","unstructured":"Bickers, B., Aukim-Hastie, C., 2009. New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res., 29(8):3289\u20133298.","journal-title":"Anticancer Res."},{"issue":"5","key":"3567_CR19","first-page":"437","volume":"20","author":"H Bonkhoff","year":"1998","unstructured":"Bonkhoff, H., 1998. Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastic prostate. Anal. Quant. Cytol. Histol., 20(5):437\u2013442.","journal-title":"Anal. Quant. Cytol. Histol."},{"issue":"2","key":"3567_CR20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)65160-7","volume":"155","author":"H Bonkhoff","year":"1999","unstructured":"Bonkhoff, H., Fixemer, T., Hunsicker, I., et al., 1999. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol., 155(2):641\u2013647. [doi:10.1016\/S0002-9440(10)65160-7]","journal-title":"Am. J. Pathol."},{"issue":"1","key":"3567_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/aja.2008.19","volume":"11","author":"N Borley","year":"2008","unstructured":"Borley, N., Feneley, M.R., 2008. Prostate cancer: diagnosis and staging. Asian J. Androl., 11(1):74\u201380. [doi:10.1038\/aja.2008.19]","journal-title":"Asian J. Androl."},{"issue":"6","key":"3567_CR22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3322\/canjclin.39.6.376","volume":"39","author":"DG Bostwick","year":"1989","unstructured":"Bostwick, D.G., 1989. The pathology of early prostate cancer. CA Cancer J. Clin., 39(6):376\u2013393. [doi:10.3322\/canjclin.39.6.376]","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"3567_CR23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I","volume":"59","author":"DG Bostwick","year":"1987","unstructured":"Bostwick, D.G., Brawer, M.K., 1987. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer, 59(4):788\u2013794. [doi:10.1002\/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I]","journal-title":"Cancer"},{"issue":"2","key":"3567_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1097-0045(199608)29:2<117::AID-PROS7>3.0.CO;2-C","volume":"29","author":"DG Bostwick","year":"1996","unstructured":"Bostwick, D.G., Pacelli, A., Lopez-Beltran, A., 1996. Molecular biology of prostatic intraepithelial neoplasia. Prostate, 29(2):117\u2013134. [doi:10.1002\/(SICI)1097-0045(199608)29:2<117::AID-PROS7>3.0.CO;2-C]","journal-title":"Prostate"},{"issue":"11","key":"3567_CR25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","volume":"9","author":"LK Boyd","year":"2012","unstructured":"Boyd, L.K., Mao, X., Lu, Y.J., 2012. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat. Rev. Urol., 9(11):652\u2013664. [doi:10.1038\/nrurol.2012.185]","journal-title":"Nat. Rev. Urol."},{"issue":"2","key":"3567_CR26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2007.09.020","volume":"179","author":"TC Brand","year":"2008","unstructured":"Brand, T.C., Bermejo, C., Canby-Hagino, E., et al., 2008. Association of polymorphisms in TGFB1 and prostate cancer prognosis. J. Urol., 179(2):754\u2013758. [doi:10.1016\/j.juro.2007.09.020]","journal-title":"J. Urol."},{"issue":"11","key":"3567_CR27","first-page":"2731","volume":"59","author":"G Brodin","year":"1999","unstructured":"Brodin, G., Dijke, P.T., Funa, K., et al., 1999. Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res., 59(11):2731\u20132738. Bryzgunova, O.E., Morozkin, E.S., Yarmoschuk, S.V., et al., 2008. Methylation-specific sequencing of GSTP1 gene promoter in circulating\/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. N. Y. Acad. Sci., 1137(1):222\u2013225. [doi:10.1196\/annals.1448.039]","journal-title":"Cancer Res."},{"issue":"5","key":"3567_CR28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L., Schopfer, A., Wagner, U., et al., 2000. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol., 31(5):578\u2013583. [doi:10.1053\/hp.2000.6698]","journal-title":"Hum. Pathol."},{"issue":"5","key":"3567_CR29","first-page":"1273","volume":"7","author":"G Buchanan","year":"2001","unstructured":"Buchanan, G., Greenberg, N.M., Scher, H.I., et al., 2001. Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res., 7(5):1273\u20131281.","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"3567_CR30","first-page":"5975","volume":"59","author":"MJ Bussemakers","year":"1999","unstructured":"Bussemakers, M.J., van Bokhoven, A., Verhaegh, G.W., et al., 1999. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res., 59(23):5975\u20135979.","journal-title":"Cancer Res."},{"issue":"4","key":"3567_CR31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jcb.21529","volume":"102","author":"G Carruba","year":"2007","unstructured":"Carruba, G., 2007. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J. Cell. Biochem., 102(4):899\u2013911. [doi:10.1002\/jcb.21529]","journal-title":"J. Cell. Biochem."},{"key":"3567_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1749-6632.2002.tb02105.x","volume":"959","author":"EL Cavalieri","year":"2006","unstructured":"Cavalieri, E.L., Rogan, E.G., 2006. A unified mechanism in the initiation of cancer. Ann. N. Y. Acad. Sci., 959:341\u2013354. [doi:10.1111\/j.1749-6632.2002.tb02105.x]","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"23","key":"3567_CR33","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","volume":"287","author":"SC Chan","year":"2012","unstructured":"Chan, S.C., Li, Y.M., Dehm, S.M., 2012. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J. Biol. Chem., 287(23):19736\u201319749. [doi:10.1074\/jbc.M112.352930]","journal-title":"J. Biol. Chem."},{"issue":"8","key":"3567_CR34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pros.22625","volume":"73","author":"CL Chen","year":"2013","unstructured":"Chen, C.L., Mahalingam, D., Osmulski, P., et al., 2013. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate, 73(8):813\u2013826. [doi:10.1002\/pros.22625]","journal-title":"Prostate"},{"issue":"1","key":"3567_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15419060490471739","volume":"11","author":"J Chen","year":"2004","unstructured":"Chen, J., De, S., Brainard, J., et al., 2004. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun. Adhes., 11(1):1\u201311. [doi:10.1080\/15419060490471739]","journal-title":"Cell Commun. Adhes."},{"issue":"38","key":"3567_CR36","doi-asserted-by":"crossref","first-page":"25576","DOI":"10.1074\/jbc.M109.043133","volume":"284","author":"S Chen","year":"2009","unstructured":"Chen, S., Kesler, C.T., Paschal, B.M., et al., 2009. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J. Biol. Chem., 284(38):25576\u201325584. [doi:10.1074\/jbc.M109.043133]","journal-title":"J. Biol. Chem."},{"issue":"9","key":"3567_CR37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ejhg.2012.281","volume":"21","author":"Y Chen","year":"2013","unstructured":"Chen, Y., Li, J., Yu, X., et al., 2013. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur. J. Hum. Genet., 21(9):929\u2013935. [doi:10.1038\/ejhg.2012.281]","journal-title":"Eur. J. Hum. Genet."},{"issue":"7051","key":"3567_CR38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","volume":"436","author":"Z Chen","year":"2005","unstructured":"Chen, Z., Trotman, L.C., Shaffer, D., et al., 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436(7051):725\u2013730. [doi:10.1038\/nature03918]","journal-title":"Nature"},{"issue":"1","key":"3567_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1541-7786.MCR-10-0235","volume":"9","author":"MA Chetram","year":"2011","unstructured":"Chetram, M.A., Odero-Marah, V., Hinton, C.V., 2011. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1\/2 in prostate cancer cells. Mol. Cancer Res., 9(1):90\u2013102. [doi:10.1158\/1541-7786.MCR-10-0235]","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"3567_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/1471-2407-12-543","volume":"12","author":"K Choucair","year":"2012","unstructured":"Choucair, K., Ejdelman, J., Brimo, F., et al., 2012. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer, 12(1):543. [doi:10.1186\/1471-2407-12-543]","journal-title":"BMC Cancer"},{"key":"3567_CR41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/aja.2008.29","volume":"11","author":"NW Clarke","year":"2009","unstructured":"Clarke, N.W., Hart, C.A., Brown, M.D., 2009. Molecular mechanisms of metastasis in prostate cancer. Asian J. Androl., 11(1):57\u201367. [doi:10.1038\/aja.2008.29]","journal-title":"Asian J. Androl."},{"issue":"1","key":"3567_CR42","doi-asserted-by":"crossref","first-page":"D1379","DOI":"10.2741\/Coleman","volume":"6","author":"KM Coleman","year":"2001","unstructured":"Coleman, K.M., Smith, C.L., 2001. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front. Biosci., 6(1):D1379\u2013D1391. [doi:10.2741\/Coleman]","journal-title":"Front. Biosci."},{"key":"3567_CR43","doi-asserted-by":"crossref","DOI":"10.17226\/11892","volume-title":"Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment","author":"Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis,Treatment","year":"2007","unstructured":"Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment, 2007. Methods, tools, and resources needed to discover and develop biomarkers. In: Nass, S.J., Moses, H.L. (Eds.), Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. National Academies Press, Washington, DC."},{"issue":"51","key":"3567_CR44","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1038\/sj.onc.1210533","volume":"26","author":"CS Craft","year":"2007","unstructured":"Craft, C.S., Romero, D., Vary, C.P., et al., 2007. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene, 26(51):7240\u20137250. [doi:10.1038\/sj.onc.1210533]","journal-title":"Oncogene"},{"issue":"3","key":"3567_CR45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/6495","volume":"5","author":"N Craft","year":"1999","unstructured":"Craft, N., Shostak, Y., Carey, M., et al., 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase. Nat. Med., 5(3):280\u2013285. [doi:10.1038\/6495]","journal-title":"Nat. Med."},{"issue":"5Suppl.","key":"3567_CR46","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.urology.2009.03.001","volume":"73","author":"ED Crawford","year":"2009","unstructured":"Crawford, E.D., 2009. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology, 73(5 Suppl.):S4\u2013S10. [doi:10.1016\/j.urology.2009.03.001]","journal-title":"Urology"},{"issue":"5","key":"3567_CR47","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.juro.2012.07.023","volume":"188","author":"ED Crawford","year":"2012","unstructured":"Crawford, E.D., Rove, K.O., Trabulsi, E.J., et al., 2012. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1962 cases. J. Urol., 188(5):1726\u20131731. [doi:10.1016\/j.juro.2012.07.023]","journal-title":"J. Urol."},{"issue":"18","key":"3567_CR48","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","volume":"65","author":"J Dai","year":"2005","unstructured":"Dai, J., Keller, J., Zhang, J., et al., 2005. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res., 65(18):8274\u20138285. [doi:10.1158\/0008-5472.CAN-05-1891]","journal-title":"Cancer Res."},{"issue":"5","key":"3567_CR49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.eururo.2011.07.011","volume":"60","author":"DC Danila","year":"2011","unstructured":"Danila, D.C., Anand, A., Sung, C.C., et al., 2011. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol., 60(5):897\u2013904. [doi:10.1016\/j.eururo.2011.07.011]","journal-title":"Eur. Urol."},{"issue":"3","key":"3567_CR50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/path.2292","volume":"214","author":"S Darby","year":"2008","unstructured":"Darby, S., Cross, S.S., Brown, N.J., et al., 2008. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J. Pathol., 214(3):394\u2013404. [doi:10.1002\/path.2292]","journal-title":"J. Pathol."},{"issue":"6","key":"3567_CR51","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0090-4295(97)00108-8","volume":"49","author":"MF Darson","year":"1997","unstructured":"Darson, M.F., Pacelli, A., Roche, P., et al., 1997. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology, 49(6):857\u2013862. [doi:10.1016\/S0090-4295(97)00108-8]","journal-title":"Urology"},{"issue":"10","key":"3567_CR52","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1055-9965.EPI-11-0373","volume":"20","author":"S Davidsson","year":"2011","unstructured":"Davidsson, S., Fiorentino, M., Andren, O., et al., 2011. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol. Biomarkers Prev., 20(10):2280\u20132287. [doi:10.1158\/1055-9965.EPI-11-0373]","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"6","key":"3567_CR53","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0002-9440(10)65517-4","volume":"155","author":"AM de Marzo","year":"1999","unstructured":"de Marzo, A.M., Marchi, V.L., Epstein, J.I., et al., 1999. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol., 155(6):1985\u20131992. [doi:10.1016\/S0002-9440(10)65517-4]","journal-title":"Am. J. Pathol."},{"issue":"2","key":"3567_CR54","first-page":"F105","volume":"1333","author":"R Derynck","year":"1997","unstructured":"Derynck, R., Feng, X.H., 1997. TGF-\u03b2 receptor signaling. Biochim. Biophys. Acta, 1333(2):F105\u2013F150.","journal-title":"Biochim. Biophys. Acta"},{"issue":"341","key":"3567_CR55","doi-asserted-by":"crossref","first-page":"c4543","DOI":"10.1136\/bmj.c4543","volume":"14","author":"M Djulbegovic","year":"2010","unstructured":"Djulbegovic, M., Beyth, R.J., Neuberger, M.M., et al., 2010. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ, 14(341):c4543. [doi:10.1136\/bmj.c4543]","journal-title":"BMJ"},{"issue":"5","key":"3567_CR56","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0022-5347(05)68239-0","volume":"162","author":"L Donaldson","year":"1999","unstructured":"Donaldson, L., Fordyce, C., Gilliland, F., et al., 1999. Association between outcome and telomere DNA content in prostate cancer. J. Urol., 162(5):1788\u20131792. [doi:10.1016\/S0022-5347(05)68239-0]","journal-title":"J. Urol."},{"issue":"18","key":"3567_CR57","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.12968\/bjon.2012.21.Sup18.S23","volume":"21","author":"L Drudge-Coates","year":"2012","unstructured":"Drudge-Coates, L., Turner, B., 2012. Prostate cancer overview. Part 2: metastatic prostate cancer. Brit. J. Nurs., 21(18):S23\u2013S24, S26-S28.","journal-title":"Brit. J. Nurs."},{"issue":"1","key":"3567_CR58","doi-asserted-by":"crossref","first-page":"268","DOI":"10.12968\/bjon.2012.21.Sup9.S23","volume":"106","author":"A Dubrovska","year":"2009","unstructured":"Dubrovska, A., Kim, S., Salamone, R.J., et al., 2009. The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. PNAS, 106(1):268\u2013273. [doi:10.1073\/pnas.0810956106]","journal-title":"PNAS"},{"issue":"2","key":"3567_CR59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1091\/mbc.02-03-0037","volume":"14","author":"S Edlund","year":"2003","unstructured":"Edlund, S., Bu, S., Schuster, N., et al., 2003. Transforming growth factor-\u03b21 (TGF-\u03b2)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-\u03b2-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol. Biol. Cell, 14(2):529\u2013544. [doi:10.1091\/mbc.02-03-0037]","journal-title":"Mol. Biol. Cell"},{"issue":"5","key":"3567_CR60","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1210\/jc.2003-030933","volume":"89","author":"SJ Ellem","year":"2004","unstructured":"Ellem, S.J., Schmitt, J.F., Pedersen, J.S., et al., 2004. Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab., 89(5):2434\u20132441. [doi:10.1210\/jc.2003-030933]","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3567_CR61","volume-title":"Firmagon","author":"European Medicines Agency","year":"2009","unstructured":"European Medicines Agency, 2009. Firmagon. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000986\/human_med_000794.jsp&mid=WC0b01ac058001d124 [Accessed on Feb. 28, 2013]."},{"key":"3567_CR62","volume-title":"Jevtana","author":"European Medicines Agency","year":"2011a","unstructured":"European Medicines Agency, 2011a. Jevtana. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002018\/human_med_001428.jsp&mid=WC0b01ac058001d124 [Accessed on Feb. 28, 2013]."},{"key":"3567_CR63","volume-title":"Zytiga","author":"European Medicines Agency","year":"2011b","unstructured":"European Medicines Agency, 2011b. Zytiga. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002321\/human_med_001499.jsp&mid=WC0b01ac058001d124 [Accessed on Feb. 28, 2013]."},{"issue":"4","key":"3567_CR64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.22571","volume":"73","author":"JA Ewald","year":"2013","unstructured":"Ewald, J.A., Desotelle, J.A., Church, D.R., et al., 2013. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. Prostate, 73(4):337\u2013345. [doi:10.1002\/pros.22571]","journal-title":"Prostate"},{"issue":"33","key":"3567_CR65","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.2174\/092986710793205363","volume":"17","author":"M Fardilha","year":"2010","unstructured":"Fardilha, M., Esteves, S.L.C., Korrodi-Gregorio, L., et al., 2010. The physiological relevance of protein phosphatase 1 and its interacting proteins to health and disease. Curr. Med. Chem., 17(33):3996\u20134017. [doi:10.2174\/092986710793205363]","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"3567_CR66","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bcp.2011.02.018","volume":"82","author":"M Fardilha","year":"2011","unstructured":"Fardilha, M., Esteves, S.L., Korrodi-Gregorio, L., et al., 2011. Identification of the human testis protein phosphatase 1 interactome. Biochem. Pharmacol., 82(10):1403\u20131415. [doi:10.1016\/j.bcp.2011.02.018]","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"3567_CR67","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/07357900701600921","volume":"25","author":"PC Faria","year":"2007","unstructured":"Faria, P.C., Saba, K., Neves, A.F., et al., 2007. Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients. Cancer Invest., 25(8):726\u2013732. [doi:10.1080\/07357900701600921]","journal-title":"Cancer Invest."},{"issue":"1","key":"3567_CR68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman, B.J., Feldman, D., 2001. The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1(1):34\u201345. [doi:10.1038\/35094009]","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"3567_CR69","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/0008-5472.CAN-12-4108","volume":"73","author":"S Feng","year":"2013","unstructured":"Feng, S., Dakhova, O., Creighton, C.J., et al., 2013. The endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res., 73(8):2551\u20132562. [doi:10.1158\/0008-5472.CAN-12-4108]","journal-title":"Cancer Res."},{"issue":"4","key":"3567_CR70","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J., Parkin, D.M., Steliarova-Foucher, E., 2010. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer, 46(4):765\u2013781. [doi:10.1016\/j.ejca.2009.12.014]","journal-title":"Eur. J. Cancer"},{"key":"3567_CR71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1471-2407-12-507","volume":"12","author":"LB Ferreira","year":"2012","unstructured":"Ferreira, L.B., Palumbo, A., de Mello, K.D., et al., 2012. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer, 12:507. [doi:10.1186\/1471-2407-12-507]","journal-title":"BMC Cancer"},{"issue":"6","key":"3567_CR72","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0022-5347(01)64775-X","volume":"157","author":"FA Ferrer","year":"1997","unstructured":"Ferrer, F.A., Miller, L.J., Andrawis, R.I., et al., 1997. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol., 157(6):2329\u20132333. [doi:10.1016\/S0022-5347(01)64775-X]","journal-title":"J. Urol."},{"issue":"3","key":"3567_CR73","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V","volume":"81","author":"C Festuccia","year":"1999","unstructured":"Festuccia, C., Bologna, M., Gravina, G.L., et al., 1999. Osteoblast conditioned media contain TGF-\u03b21 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int. J. Cancer, 81(3):395\u2013403. [doi:10.1002\/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.3.CO;2-M]","journal-title":"Int. J. Cancer"},{"issue":"2","key":"3567_CR74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bjc.2012.598","volume":"108","author":"G Fisher","year":"2013","unstructured":"Fisher, G., Yang, Z.H., Kudahetti, S., et al., 2013. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Brit. J. Cancer, 108(2):271\u2013277. [doi:10.1038\/bjc.2012.598]","journal-title":"Brit. J. Cancer"},{"issue":"2","key":"3567_CR75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pros.10171","volume":"54","author":"T Fixemer","year":"2003","unstructured":"Fixemer, T., Remberger, K., Bonkhoff, H., 2003. Differential expression of the estrogen receptor beta (ER\u03b2) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate, 54(2):79\u201387. [doi:10.1002\/pros.10171]","journal-title":"Prostate"},{"issue":"2","key":"3567_CR76","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.ju.0000143195.49685.ce","volume":"173","author":"CA Fordyce","year":"2005","unstructured":"Fordyce, C.A., Heaphy, C.M., Joste, N.E., et al., 2005. Association between cancer-free survival and telomere DNA content in prostate tumors. J. Urol., 173(2):610\u2013614. [doi:10.1097\/01.ju.0000143195.49685.ce]","journal-title":"J. Urol."},{"issue":"1","key":"3567_CR77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/003655900750169284","volume":"34","author":"CS Foster","year":"2000","unstructured":"Foster, C.S., Bostwick, D.G., Bonkhoff, H., et al., 2000. Cellular and molecular pathology of prostate cancer precursors. Scand. J. Urol. Nephrol. Suppl., 34(1):19\u201343. [doi:10.1080\/003655900750169284]","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"issue":"4","key":"3567_CR78","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0194-5998(99)70238-X","volume":"121","author":"S Gabel","year":"1999","unstructured":"Gabel, S., Benefield, J., Meisinger, J., et al., 1999. Protein phosphatases 1 and 2A maintain endothelial cells in a resting state, limiting the motility that is needed for the morphogenic process of angiogenesis. Otolaryngol. Head Neck Surg., 121(4):463\u2013468. [doi:10.1016\/S0194-5998(99)70238-X]","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"13","key":"3567_CR79","first-page":"5038","volume":"61","author":"J Gao","year":"2001","unstructured":"Gao, J., Arnold, J.T., Isaacs, J.T., 2001. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res., 61(13):5038\u20135044.","journal-title":"Cancer Res."},{"issue":"4","key":"3567_CR80","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbrc.2003.09.132","volume":"310","author":"N Gao","year":"2003","unstructured":"Gao, N., Zhang, Z., Jiang, B.H., et al., 2003. Role of PI3K\/AKT\/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun., 310(4):1124\u20131132. [doi:10.1016\/j.bbrc.2003.09.132]","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"3567_CR81","first-page":"111","volume":"6","author":"X Gao","year":"1995","unstructured":"Gao, X., Zacharek, A., Grignon, D., et al., 1995. High-frequency of loss of expression and allelic deletion of the apc and mcc genes in human prostate-cancer. Int. J. Oncol., 6(1):111\u2013117.","journal-title":"Int. J. Oncol."},{"issue":"3","key":"3567_CR82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/ctrv.2000.0213","volume":"27","author":"P Garnero","year":"2001","unstructured":"Garnero, P., 2001. Markers of bone turnover in prostate cancer. Cancer Treat. Rev., 27(3):187\u2013192, Discussion 193-186. [doi:10.1053\/ctrv.2000.0213]","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"3567_CR83","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","volume":"82","author":"P Garnero","year":"2000","unstructured":"Garnero, P., Buchs, N., Zekri, J., et al., 2000. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Brit. J. Cancer, 82(4):858\u2013864. [doi:10.1054\/bjoc.1999.1012]","journal-title":"Brit. J. Cancer"},{"issue":"33","key":"3567_CR84","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/sj.onc.1205663","volume":"21","author":"VJ Gnanapragasam","year":"2002","unstructured":"Gnanapragasam, V.J., Robson, C.N., Neal, D.E., et al., 2002. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene, 21(33):5069\u20135080. [doi:10.1038\/sj.onc.1205663]","journal-title":"Oncogene"},{"issue":"1","key":"3567_CR85","first-page":"267","volume":"38","author":"A Goc","year":"2011","unstructured":"Goc, A., Al-Husein, B., Kochuparambil, S.T., et al., 2011. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int. J. Oncol., 38(1):267\u2013277. [doi:10.3892\/ijo_00000847]","journal-title":"Int. J. Oncol."},{"issue":"3","key":"3567_CR86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0377-4929.85078","volume":"54","author":"MM Goel","year":"2011","unstructured":"Goel, M.M., Agrawal, D., Natu, S.M., et al., 2011. Hepsin immunohistochemical expression in prostate cancer in relation to Gleason\u2019s grade and serum prostate specific antigen. Indian J. Pathol. Microbiol., 54(3):476\u2013481. [doi:10.4103\/0377-4929.85078]","journal-title":"Indian J. Pathol. Microbiol."},{"key":"3567_CR87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-61779-612-8_4","volume":"863","author":"W Goering","year":"2012","unstructured":"Goering, W., Kloth, M., Schulz, W.A., 2012. DNA methylation changes in prostate cancer. Methods Mol. Biol., 863:47\u201366. [doi:10.1007\/978-1-61779-612-8_4]","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"3567_CR88","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/pcan.2012.3","volume":"15","author":"A Gordanpour","year":"2012","unstructured":"Gordanpour, A., Nam, R.K., Sugar, L., et al., 2012. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis., 15(4):314\u2013319. [doi:10.1038\/pcan.2012.3]","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"3","key":"3567_CR89","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/modpathol.3800052","volume":"17","author":"DJ Grignon","year":"2004","unstructured":"Grignon, D.J., 2004. Unusual subtypes of prostate cancer. Modern Pathol., 17(3):316\u2013327. [doi:10.1038\/modpathol.3800052]","journal-title":"Modern Pathol."},{"issue":"4","key":"3567_CR90","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2353\/ajpath.2010.090653","volume":"176","author":"L Gu","year":"2010","unstructured":"Gu, L., Dagvadorj, A., Lutz, J., et al., 2010. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am. J. Pathol., 176(4):1959\u20131972. [doi:10.2353\/ajpath.2010.090653]","journal-title":"Am. J. Pathol."},{"issue":"3","key":"3567_CR91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/pcan.2011.64","volume":"15","author":"G Gueron","year":"2012","unstructured":"Gueron, G., de Siervi, A., Vazquez, E., 2012. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis., 15(3):213\u2013221. [doi:10.1038\/pcan.2011.64]","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"3567_CR92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO;2-D","volume":"71","author":"Y Guo","year":"1997","unstructured":"Guo, Y., Jacobs, S.C., Kyprianou, N., 1997. Down-regulation of protein and mRNA expression for transforming growth factor-\u03b2 (TGF-\u03b21) type I and type II receptors in human prostate cancer. Int. J. Cancer, 71(4):573\u2013579. [doi:10.1002\/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO;2-D]","journal-title":"Int. J. Cancer"},{"issue":"6","key":"3567_CR93","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo, Z., Yang, X., Sun, F., et al., 2009. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res., 69(6):2305\u20132313. [doi:10.1158\/0008-5472.CAN-08-3795]","journal-title":"Cancer Res."},{"issue":"2","key":"3567_CR94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CEJ.0b013e32834a8002","volume":"21","author":"G Gupta-Elera","year":"2012","unstructured":"Gupta-Elera, G., Garrett, A.R., Robison, R.A., et al., 2012. The role of oxidative stress in prostate cancer. Eur. J. Cancer Prev., 21(2):155\u2013162. [doi:10.1097\/CEJ.0b013e32834a8002]","journal-title":"Eur. J. Cancer Prev."},{"issue":"19","key":"3567_CR95","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/djm153","volume":"99","author":"GP Haas","year":"2007","unstructured":"Haas, G.P., Delongchamps, N.B., Jones, R.F., et al., 2007. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst., 99(19):1484\u20131489. [doi:10.1093\/jnci\/djm153]","journal-title":"J. Natl. Cancer Inst."},{"issue":"19","key":"3567_CR96","first-page":"4427","volume":"57","author":"FC Hamdy","year":"1997","unstructured":"Hamdy, F.C., Autzen, P., Robinson, M.C., et al., 1997. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res., 57(19):4427\u20134431.","journal-title":"Cancer Res."},{"issue":"31","key":"3567_CR97","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/sj.onc.1206730","volume":"22","author":"SA Hayes","year":"2003","unstructured":"Hayes, S.A., Huang, X., Kambhampati, S., et al., 2003. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene, 22(31):4841\u20134850. [doi:10.1038\/sj.onc.1206730]","journal-title":"Oncogene"},{"issue":"3","key":"3567_CR98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12032-008-9120-9","volume":"26","author":"HC He","year":"2009","unstructured":"He, H.C., Bi, X.C., Zheng, Z.W., et al., 2009. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer. Med. Oncol., 26(3):303\u2013308. [doi:10.1007\/s12032-008-9120-9]","journal-title":"Med. Oncol."},{"issue":"7","key":"3567_CR99","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","volume":"28","author":"HV Heemers","year":"2007","unstructured":"Heemers, H.V., Tindall, D.J., 2007. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Rev., 28(7):778\u2013808. [doi:10.1210\/er.2007-0019]","journal-title":"Endocrine Rev."},{"issue":"2","key":"3567_CR100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1464-410X.2006.06604.x","volume":"99","author":"A Hegele","year":"2007","unstructured":"Hegele, A., Wahl, H.G., Varga, Z., et al., 2007. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int., 99(2):330\u2013334. [doi:10.1111\/j.1464-410X.2006.06604.x]","journal-title":"BJU Int."},{"key":"3567_CR101","doi-asserted-by":"crossref","unstructured":"Heidenreich, A., Bastian, P.J., Bellmunt, J., et al., 2012. Guidelines on prostate cancer. European Association of Urology, p.35-102. Available from http:\/\/www.uroweb.org\/guidelines\/online-guidelines\/Heinlein, C.A., Chang, C., 2004. Androgen receptor in prostate cancer. Endocrine Rev., 25(2):276\u2013308. [doi:10.1210\/er.2002-0032]","DOI":"10.1210\/er.2002-0032"},{"issue":"4","key":"3567_CR102","doi-asserted-by":"crossref","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E H\u00f6rnberg","year":"2011","unstructured":"H\u00f6rnberg, E., Ylitalo, E.B., Crnalic, S., et al., 2011. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE, 6(4):e19059. [doi:10.1371\/journal.pone.0019059]","journal-title":"PLoS ONE"},{"issue":"14","key":"3567_CR103","first-page":"5331","volume":"61","author":"LG Horvath","year":"2001","unstructured":"Horvath, L.G., Henshall, S.M., Lee, C.S., et al., 2001. Frequent loss of estrogen receptor-\u03b2 expression in prostate cancer. Cancer Res., 61(14):5331\u20135335.","journal-title":"Cancer Res."},{"issue":"3","key":"3567_CR104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pros.10361","volume":"59","author":"LG Horvath","year":"2004","unstructured":"Horvath, L.G., Henshall, S.M., Kench, J.G., et al., 2004. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 59(3):234\u2013242. [doi:10.1002\/pros.10361]","journal-title":"Prostate"},{"key":"3567_CR105","first-page":"232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins, C., Hodges, C.V., 1972. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin., 22(4):232\u2013240. [doi:10.3322\/canjclin.22.4.232]","journal-title":"The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin."},{"issue":"6","key":"3567_CR106","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-410X.2010.10032.x","volume":"107","author":"D Ilic","year":"2011","unstructured":"Ilic, D., O\u2019Connor, D., Green, S., et al., 2011. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int., 107(6):882\u2013891. [doi:10.1111\/j.1464-410X.2010.10032.x]","journal-title":"BJU Int."},{"issue":"1","key":"3567_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-6-39","volume":"6","author":"U Jariwala","year":"2007","unstructured":"Jariwala, U., Prescott, J., Jia, L., et al., 2007. Identification of novel androgen receptor target genes in prostate cancer. Mol. Cancer, 6(1):1\u201315. [doi:10.1186\/1476-4598-6-39]","journal-title":"Mol. Cancer"},{"issue":"2","key":"3567_CR108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A., Bray, F., Center, M.M., et al., 2011. Global cancer statistics. CA Cancer J. Clin., 61(2):69\u201390. [doi:10.3322\/caac.20107]","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"3567_CR109","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/pros.20276","volume":"65","author":"K Jennbacken","year":"2005","unstructured":"Jennbacken, K., Vallbo, C., Wang, W., et al., 2005. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate, 65(2):110\u2013116. [doi:10.1002\/pros.20276]","journal-title":"Prostate"},{"key":"3567_CR110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.juro.2012.06.004","volume":"188","author":"Q Jiang","year":"2012","unstructured":"Jiang, Q., Yeh, S., Wang, X., et al., 2012. Targeting androgen receptor leads to suppression of prostate cancer via induction of autophagy. J. Urol., 188(4):1361\u20131368. [doi:10.1016\/j.juro.2012.06.004]","journal-title":"J. Urol."},{"key":"3567_CR111","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/00365599.2012.669791","volume":"46","author":"A Josefsson","year":"2012","unstructured":"Josefsson, A., Wikstrom, P., Egevad, L., et al., 2012. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand. J. Urol. Nephrol., 46(4):247\u2013257. [doi:10.3109\/00365599.2012.669791]","journal-title":"Scand. J. Urol. Nephrol."},{"key":"3567_CR112","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.1997.tb00216.x","volume":"4","author":"Y Kageyama","year":"1997","unstructured":"Kageyama, Y., Kamata, S., Yonese, J., et al., 1997. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int. J. Urol., 4(4):407\u2013410. [doi:10.1111\/j.1442-2042.1997.tb00216.x]","journal-title":"Int. J. Urol."},{"issue":"6","key":"3567_CR113","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1073\/pnas.061305498","volume":"98","author":"HY Kang","year":"2001","unstructured":"Kang, H.Y., Lin, H.K., Hu, Y.C., et al., 2001. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. PNAS, 98(6):3018\u20133023. [doi:10.1073\/pnas.061305498]","journal-title":"PNAS"},{"issue":"5","key":"3567_CR114","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P.W., Higano, C.S., Shore, N.D., et al., 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 363(5):411\u2013422. [doi:10.1056\/NEJMoa1001294]","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"3567_CR115","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/1078-0432.CCR-07-0901","volume":"14","author":"JA Karam","year":"2008","unstructured":"Karam, J.A., Svatek, R.S., Karakiewicz, P.I., et al., 2008. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin. Cancer Res., 14(5):1418\u20131422. [doi:10.1158\/1078-0432.CCR-07-0901]","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"3567_CR116","doi-asserted-by":"crossref","first-page":"e51680","DOI":"10.1371\/journal.pone.0051680","volume":"7","author":"R Kazma","year":"2012","unstructured":"Kazma, R., Mefford, J.A., Cheng, I., et al., 2012. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS ONE, 7(12):e51680. [doi:10.1371\/journal.pone.0051680]","journal-title":"PLoS ONE"},{"issue":"7","key":"3567_CR117","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/0008-5472.CAN-07-1349","volume":"68","author":"KA Kelly","year":"2008","unstructured":"Kelly, K.A., Setlur, S.R., Ross, R., et al., 2008. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res., 68(7):2286\u20132291. [doi:10.1158\/0008-5472.CAN-07-1349]","journal-title":"Cancer Res."},{"issue":"7","key":"3567_CR118","first-page":"1625","volume":"4","author":"IY Kim","year":"1998","unstructured":"Kim, I.Y., Ahn, H.J., Lang, S., et al., 1998. Loss of expression of transforming growth factor-\u03b2 receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res., 4(7):1625\u20131630.","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"3567_CR119","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/cancers4041229","volume":"4","author":"J Kim","year":"2012","unstructured":"Kim, J., Bilusic, M., Heery, C., et al., 2012. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. Cancers, 4(4):1229\u20131246. [doi:10.3390\/cancers4041229]","journal-title":"Cancers"},{"issue":"2","key":"3567_CR120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2004.07.008","volume":"6","author":"O Klezovitch","year":"2004","unstructured":"Klezovitch, O., Chevillet, J., Mirosevich, J., et al., 2004. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell, 6(2):185\u2013195. [doi:10.1016\/j.ccr.2004.07.008]","journal-title":"Cancer Cell"},{"key":"3567_CR121","volume-title":"Advances in Cancer Research","author":"BS Knudsen","year":"2010","unstructured":"Knudsen, B.S., Vasioukhin, V., 2010. Mechanisms of prostate cancer initiation and progression. In: Woude, G.F.V., Klein, G. (Eds.), Advances in Cancer Research. Academic Press, United States of America."},{"issue":"11","key":"3567_CR122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4111\/kju.2011.52.11.736","volume":"52","author":"O Koca","year":"2011","unstructured":"Koca, O., Caliskan, S., Ozturk, M.I., et al., 2011. Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy. Korean J. Urol., 52(11):736\u2013740. [doi:10.4111\/kju.2011.52.11.736]","journal-title":"Korean J. Urol."},{"key":"3567_CR123","first-page":"199","volume-title":"Essentials of Cell Signaling","author":"L Korrodi-Gregorio","year":"2012","unstructured":"Korrodi-Gregorio, L., Teixeira, A.L., Medeiros, R., 2012. TGF\u03b2 pathway. In: Fardilha, M., da Cruz e Silva, O.A. (Eds.), Essentials of Cell Signaling. Afrontamento, Aveiro, p.199\u2013234 (in Portuguese)."},{"key":"3567_CR124","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1073\/pnas.93.12.5925","volume":"93","author":"GG Kuiper","year":"1996","unstructured":"Kuiper, G.G., Enmark, E., Pelto-Huikko, M., et al., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. PNAS, 93(12):5925\u20135930. [doi:10.1073\/pnas.93.12.5925]","journal-title":"PNAS"},{"issue":"2","key":"3567_CR125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.urolonc.2008.01.012","volume":"27","author":"M Kumano","year":"2009","unstructured":"Kumano, M., Miyake, H., Muramaki, M., et al., 2009. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol., 27(2):180\u2013186. [doi:10.1016\/j.urolonc.2008.01.012]","journal-title":"Urol. Oncol."},{"issue":"1","key":"3567_CR126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10585-010-9356-6","volume":"28","author":"M Lakshman","year":"2011","unstructured":"Lakshman, M., Huang, X., Ananthanarayanan, V., et al., 2011. Endoglin suppresses human prostate cancer metastasis. Clin. Exp. Metast., 28(1):39\u201353. [doi:10.1007\/s10585-010-9356-6]","journal-title":"Clin. Exp. Metast."},{"issue":"9","key":"3567_CR127","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0960-9822(00)00470-X","volume":"10","author":"M Landstrom","year":"2000","unstructured":"Landstrom, M., Heldin, N.E., Bu, S., et al., 2000. Smad7 mediates apoptosis induced by transforming growth factor \u03b2 in prostatic carcinoma cells. Curr. Biol., 10(9):535\u2013538. [doi:10.1016\/S0960-9822(00)00470-X]","journal-title":"Curr. Biol."},{"issue":"3","key":"3567_CR128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1541-7786.141.2.3","volume":"2","author":"EM Langenfeld","year":"2004","unstructured":"Langenfeld, E.M., Langenfeld, J., 2004. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors11NIH K22 grant CA91919-01A1 and UMDNJ foundation to J. Langenfeld. Mol. Cancer Res., 2(3):141\u2013149.","journal-title":"Langenfeld. Mol. Cancer Res."},{"issue":"6","key":"3567_CR129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/j.1939-4640.1981.tb00633.x","volume":"2","author":"C Lee","year":"1981","unstructured":"Lee, C., Prins, G.S., Henneberry, M.O., et al., 1981. Effect of estradiol on the rat prostate in the presence and absence of testosterone and pituitary. J. Androl., 2(6):293\u2013299. [doi:10.1002\/j.1939-4640.1981.tb00633.x]","journal-title":"J. Androl."},{"issue":"4","key":"3567_CR130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<285::AID-PROS9>3.0.CO;2-7","volume":"39","author":"C Lee","year":"1999","unstructured":"Lee, C., Sintich, S.M., Mathews, E.P., et al., 1999. Transforming growth factor-\u03b2 in benign and malignant prostate. Prostate, 39(4):285\u2013290. [doi:10.1002\/(SICI)1097-0045(19990601)39:4<285::AID-PROS9>3.0.CO;2-7]","journal-title":"Prostate"},{"issue":"20","key":"3567_CR131","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/j.1939-4640.1981.tb00633.x","volume":"25","author":"A Leiblich","year":"2006","unstructured":"Leiblich, A., Cross, S.S., Catto, J.W., et al., 2006. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene, 25(20):2953\u20132960. [doi:10.1038\/sj.onc.1209262]","journal-title":"Oncogene"},{"issue":"Suppl.3","key":"3567_CR132","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.3747\/co.19.1281","volume":"19","author":"R Leibowitz-Amit","year":"2012","unstructured":"Leibowitz-Amit, R., Joshua, A.M., 2012. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr. Oncol., 19(Suppl. 3):S22\u2013S31. [doi:10.3747\/co.19.1281]","journal-title":"Curr. Oncol."},{"issue":"3","key":"3567_CR133","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1677\/ERC-09-0294","volume":"17","author":"YK Leung","year":"2010a","unstructured":"Leung, Y.K., Lam, H.M., Wu, S., et al., 2010a. Estrogen receptor \u03b22 and \u03b25 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr. Relat. Cancer, 17(3):675\u2013689. [doi:10. 1677\/erc-09-0294]","journal-title":"Endocr. Relat. Cancer"},{"key":"3567_CR134","volume-title":"ENDO2010 92th Annual Meeting","author":"YK Leung","year":"2010b","unstructured":"Leung, Y.K., Lee, M.T., Wang, J., et al., 2010b. Post-transcriptional regulation of estrogen receptor \u03b2 isoforms in prostate cancer. ENDO2010 92th Annual Meeting, San Diego, California."},{"issue":"24","key":"3567_CR135","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1128\/MCB.23.24.9389-9404.2003","volume":"23","author":"L Li","year":"2003","unstructured":"Li, L., Ren, C.H., Tahir, S.A., et al., 2003. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine\/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol., 23(24):9389\u20139404. [doi:10.1128\/MCB.23.24.9389-9404.2003]","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"3567_CR136","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.pcan.4500776","volume":"8","author":"L Li","year":"2005","unstructured":"Li, L., Ittmann, M.M., Ayala, G., et al., 2005. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis., 8(2):108\u2013118. [doi:10.1038\/sj.pcan.4500776]","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"3567_CR137","doi-asserted-by":"crossref","first-page":"952.e1","DOI":"10.1016\/j.urology.2012.06.017","volume":"80","author":"W Li","year":"2012","unstructured":"Li, W., Wang, X., Li, B., et al., 2012. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer. Urology, 80(4):952.e1\u2013952.e7. [doi:10.1016\/j.urology.2012.06.017]","journal-title":"Urology"},{"issue":"7287","key":"3567_CR138","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature08815","volume":"464","author":"HK Lin","year":"2010","unstructured":"Lin, H.K., Chen, Z., Wang, G., et al., 2010. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 464(7287):374\u2013379. [doi:10.1038\/nature08815]","journal-title":"Nature"},{"issue":"12","key":"3567_CR139","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1631\/jzus.2007.B0853","volume":"8","author":"AJ Liu","year":"2007","unstructured":"Liu, A.J., Furusato, B., Ravindranath, L., et al., 2007. Quantitative analysis of a panel of gene expression in prostate cancer-with emphasis on NPY expression analysis. J. Zhejiang Univ.-Sci. B, 8(12):853\u2013859. [doi:10.1631\/jzus.2007.B0853]","journal-title":"J. Zhejiang Univ.-Sci. B"},{"issue":"10","key":"3567_CR140","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/ijc.25908","volume":"129","author":"L Liu","year":"2011","unstructured":"Liu, L., Kron, K.J., Pethe, V.V., et al., 2011. Association of tissue promoter methylation levels of APC, TGF\u03b22, HOXD3 and RASSF1A with prostate cancer progression. Int. J. Cancer, 129(10):2454\u20132462. [doi:10.1002\/ijc.25908]","journal-title":"Int. J. Cancer"},{"issue":"2","key":"3567_CR141","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000329069","volume":"87","author":"L Liwei","year":"2011","unstructured":"Liwei, L., Chunyu, L., Jie, L., et al., 2011. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis. Urol. Int., 87(2):159\u2013164. [doi:10.1159\/000329069]","journal-title":"Urol. Int."},{"issue":"6","key":"3567_CR142","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/carcin\/bgi288","volume":"27","author":"KL Lockett","year":"2006","unstructured":"Lockett, K.L., Hall, M.C., Clark, P.E., et al., 2006. DNA damage levels in prostate cancer cases and controls. Carcinogenesis, 27(6):1187\u20131193. [doi:10.1093\/carcin\/bgi288]","journal-title":"Carcinogenesis"},{"key":"3567_CR143","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.83937","volume":"10","author":"PE Lonergan","year":"2011","unstructured":"Lonergan, P.E., Tindall, D.J., 2011. Androgen receptor signaling in prostate cancer development and progression. J. Carcinogen., 10:20. [doi:10.4103\/1477-3163.83937]","journal-title":"J. Carcinogen."},{"issue":"6","key":"3567_CR144","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1464-410X.2007.07122.x","volume":"100","author":"JI Lopez","year":"2007","unstructured":"Lopez, J.I., 2007. Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. BJU Int., 100(6):1272\u20131276. [doi:10.1111\/j.1464-410X.2007.07122.x]","journal-title":"BJU Int."},{"issue":"20","key":"3567_CR145","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","volume":"17","author":"TL Lotan","year":"2011","unstructured":"Lotan, T.L., Gurel, B., Sutcliffe, S., et al., 2011. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin. Cancer Res., 17(20):6563\u20136573. [doi:10.1158\/1078-0432.CCR-11-1244]","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"3567_CR146","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ajpath.2012.11.025","volume":"182","author":"TL Lu","year":"2013","unstructured":"Lu, T.L., Huang, Y.F., You, L.R., et al., 2013. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am. J. Pathol., 182(3):975\u2013991. [doi:10.1016\/j.ajpath.2012.11.025]","journal-title":"Am. J. Pathol."},{"issue":"4","key":"3567_CR147","first-page":"270","volume":"67","author":"N Lumen","year":"2012","unstructured":"Lumen, N., Fonteyne, V., de Meerleer, G., et al., 2012. Screening and early diagnosis of prostate cancer: an update. Acta Clin. Belg., 67(4):270\u2013275.","journal-title":"Acta Clin. Belg."},{"issue":"2","key":"3567_CR148","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2011.11.021","volume":"317","author":"Y Ma","year":"2012","unstructured":"Ma, Y., Cheng, Q., Ren, Z., et al., 2012. Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett., 317(2):150\u2013156. [doi:10.1016\/j.canlet.2011.11.021]","journal-title":"Cancer Lett."},{"issue":"4","key":"3567_CR149","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4103\/0377-4929.91492","volume":"54","author":"SH Madani","year":"2011","unstructured":"Madani, S.H., Ameli, S., Khazaei, S., et al., 2011. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J. Pathol. Microbiol., 54(4):688\u2013691. [doi:10.4103\/0377-4929.91492]","journal-title":"Indian J. Pathol. Microbiol."},{"issue":"50","key":"3567_CR150","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.1038\/sj.onc.1209096","volume":"24","author":"PK Majumder","year":"2005","unstructured":"Majumder, P.K., Sellers, W.R., 2005. Akt-regulated pathways in prostate cancer. Oncogene, 24(50):7465\u20137474. [doi:10.1038\/sj.onc.1209096]","journal-title":"Oncogene"},{"issue":"4","key":"3567_CR151","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2010.02.030","volume":"17","author":"P Mak","year":"2010","unstructured":"Mak, P., Leav, I., Pursell, B., et al., 2010. ER\u03b2 impedes prostate cancer EMT by destabilizing HIF-1\u03b1 and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell, 17(4):319\u2013332. [doi:10.1016\/j.ccr.2010.02.030]","journal-title":"Cancer Cell"},{"key":"3567_CR152","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.med.60.042307.110714","volume":"60","author":"DV Makarov","year":"2009","unstructured":"Makarov, D.V., Loeb, S., Getzenberg, R.H., et al., 2009. Biomarkers for prostate cancer. Ann. Rev. Med., 60:139\u2013151. [doi:10.1146\/annurev.med.60.042307.110714]","journal-title":"Ann. Rev. Med."},{"issue":"1","key":"3567_CR153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1464-410X.2007.06544.x","volume":"99","author":"PA Mancuso","year":"2007","unstructured":"Mancuso, P.A., Chabert, C., Chin, P., et al., 2007. Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation. BJU Int., 99(1):49\u201352. [doi:10.1111\/j.1464-410X.2007.06544.x]","journal-title":"BJU Int."},{"issue":"8","key":"3567_CR154","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/138920206779315737","volume":"7","author":"M Marino","year":"2006","unstructured":"Marino, M., Galluzzo, P., Ascenzi, P., 2006. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics, 7(8):497\u2013508.","journal-title":"Curr. Genomics"},{"issue":"8","key":"3567_CR155","doi-asserted-by":"crossref","first-page":"e23144","DOI":"10.1371\/journal.pone.0023144","volume":"6","author":"RB Marques","year":"2011","unstructured":"Marques, R.B., Dits, N.F., Erkens-Schulze, S., et al., 2011. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS ONE, 6(8):e23144. [doi:10.1371\/journal.pone.0023144]","journal-title":"PLoS ONE"},{"issue":"7","key":"3567_CR156","doi-asserted-by":"crossref","first-page":"e40769","DOI":"10.1371\/journal.pone.0040769","volume":"7","author":"C Martin-Granados","year":"2012","unstructured":"Martin-Granados, C., Prescott, A.R., van Dessel, N., et al., 2012. A role for PP1\/NIPP1 in steering migration of human cancer cells. PLoS ONE, 7(7):e40769. [doi:10.1371\/journal.pone.0040769]","journal-title":"PLoS ONE"},{"issue":"1","key":"3567_CR157","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pros.20030","volume":"59","author":"H Masuda","year":"2004","unstructured":"Masuda, H., Fukabori, Y., Nakano, K., et al., 2004. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate, 59(1):101\u2013106. [doi:10.1002\/pros.20030]","journal-title":"Prostate"},{"key":"3567_CR158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-5-24","volume":"5","author":"MD Mattie","year":"2006","unstructured":"Mattie, M.D., Benz, C.C., Bowers, J., et al., 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer, 5:24. [doi:10.1186\/1476-4598-5-24]","journal-title":"Mol. Cancer"},{"issue":"6","key":"3567_CR159","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/mol.108.053140","volume":"75","author":"JL McConnell","year":"2009","unstructured":"McConnell, J.L., Wadzinski, B.E., 2009. Targeting protein serine\/threonine phosphatases for drug development. Mol. Pharmacol., 75(6):1249\u20131261. [doi:10.1124\/mol.108.053140]","journal-title":"Mol. Pharmacol."},{"key":"3567_CR160","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1073\/pnas.0905524107","volume":"107","author":"SJ McPherson","year":"2010","unstructured":"McPherson, S.J., Hussain, S., Balanathan, P., et al., 2010. Estrogen receptor-\u03b2 activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNF\u03b1 mediated. PNAS, 107(7):3123\u20133128. [doi:10.1073\/pnas.0905524107]","journal-title":"PNAS"},{"issue":"2","key":"3567_CR161","first-page":"96","volume":"12","author":"VW Merz","year":"1994","unstructured":"Merz, V.W., Arnold, A.M., Studer, U.E., 1994. Differential expression of transforming growth factor-\u03b21 and \u03b23 as well as C-FOS mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J. Urol., 12(2):96\u201398.","journal-title":"World J. Urol."},{"issue":"1","key":"3567_CR162","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopha.2003.11.001","volume":"58","author":"HA Meyer","year":"2004","unstructured":"Meyer, H.A., Ahrens-Fath, I., Sommer, A., et al., 2004. Novel molecular aspects of prostate carcinogenesis. Biomed. Pharmacother., 58(1):10\u201316. [doi:10.1016\/j.biopha.2003.11.001]","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"3567_CR163","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/cncr.11635","volume":"98","author":"DC Miller","year":"2003","unstructured":"Miller, D.C., Hafez, K.S., Stewart, A., et al., 2003. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer, 98(6):1169\u20131178. [doi:10.1002\/cncr.11635]","journal-title":"Cancer"},{"issue":"30","key":"3567_CR164","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell, P.S., Parkin, R.K., Kroh, E.M., et al., 2008. Circulating microRNAs as stable blood-based markers for cancer detection. PNAS, 105(30):10513\u201310518. [doi:10.1073\/pnas.0804549105]","journal-title":"PNAS"},{"issue":"4","key":"3567_CR165","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.ju.0000116617.32728.ca","volume":"171","author":"H Miyake","year":"2004","unstructured":"Miyake, H., Hara, I., Kamidono, S., et al., 2004. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J. Urol., 171(4):1533\u20131536. [doi:10.1097\/01.ju.0000116617.32728.ca]","journal-title":"J. Urol."},{"issue":"1","key":"3567_CR166","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000148260.69779.c5","volume":"173","author":"CK Moore","year":"2005","unstructured":"Moore, C.K., Karikehalli, S., Nazeer, T., et al., 2005. Prognostic significance of high grade prostatic intrae-pithelial neoplasia and atypical small acinar proliferation in the contemporary era. J. Urol., 173(1):70\u201372. [doi:10.1097\/01.ju.0000148260.69779.c5]","journal-title":"J. Urol."},{"issue":"2","key":"3567_CR167","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/156800909787580999","volume":"9","author":"TM Morgan","year":"2009","unstructured":"Morgan, T.M., Koreckij, T.D., Corey, E., 2009. Targeted therapy for advanced prostate cancer: inhibition of the PI3K\/Akt\/mTOR pathway. Curr. Cancer Drug Targets, 9(2):237\u2013249.","journal-title":"Curr. Cancer Drug Targets"},{"issue":"4","key":"3567_CR168","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000066230","volume":"63","author":"SJ Moschos","year":"2002","unstructured":"Moschos, S.J., Mantzoros, C.S., 2002. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 63(4):317\u2013332. [doi:10.1159\/000066230]","journal-title":"Oncology"},{"issue":"5","key":"3567_CR169","first-page":"287","volume":"53","author":"K Naruse","year":"2007","unstructured":"Naruse, K., Yamada, Y., Aoki, S., et al., 2007. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo, 53(5):287\u2013292.","journal-title":"Hinyokika Kiyo"},{"issue":"4","key":"3567_CR170","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMra021562","volume":"349","author":"WG Nelson","year":"2003","unstructured":"Nelson, W.G., de Marzo, A.M., Isaacs, W.B., 2003. Prostate cancer. N. Engl. J. Med., 349(4):366\u2013381. [doi:10.1056\/NEJMra021562]","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"3567_CR171","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.biocel.2007.01.005","volume":"39","author":"M Nieto","year":"2007","unstructured":"Nieto, M., Finn, S., Loda, M., et al., 2007. Prostate cancer: re-focusing on androgen receptor signaling. Int. J. Biochem. Cell Biol., 39(9):1562\u20131568. [doi:10.1016\/j.biocel.2007.01.005]","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"3567_CR172","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12672-013-0131-4","volume":"4","author":"MD Nyquist","year":"2013","unstructured":"Nyquist, M.D., Dehm, S.M., 2013. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Hormones Cancer, 4(2):61\u201369. [doi:10.1007\/s12672-013-0131-4]","journal-title":"Hormones Cancer"},{"issue":"3C","key":"3567_CR173","first-page":"2945","volume":"23","author":"S Ohta","year":"2003","unstructured":"Ohta, S., Fuse, H., Fujiuchi, Y., et al., 2003. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer. Anticancer Res., 23(3C):2945\u20132950.","journal-title":"Anticancer Res."},{"issue":"10","key":"3567_CR174","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mc.20313","volume":"46","author":"ST Okino","year":"2007","unstructured":"Okino, S.T., Pookot, D., Majid, S., et al., 2007. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol. Carcinogen., 46(10):839\u2013846. [doi:10.1002\/mc.20313]","journal-title":"Mol. Carcinogen."},{"issue":"6","key":"3567_CR175","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.urology.2007.07.019","volume":"70","author":"OT Okotie","year":"2007","unstructured":"Okotie, O.T., Roehl, K.A., Han, M., et al., 2007. Characteristics of prostate cancer detected by digital rectal examination only. Urology, 70(6):1117\u20131120. [doi:10.1016\/j.urology.2007.07.019]","journal-title":"Urology"},{"issue":"3","key":"3567_CR176","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2012.09.005","volume":"39","author":"S Oudard","year":"2013","unstructured":"Oudard, S., 2013. Progress in emerging therapies for advanced prostate cancer. Cancer Treatment Rev., 39(3):275\u2013289. [doi:10.1016\/j.ctrv.2012.09.005]","journal-title":"Cancer Treatment Rev."},{"issue":"2","key":"3567_CR177","first-page":"143","volume":"64","author":"G Pace","year":"2012","unstructured":"Pace, G., Pomante, R., Vicentini, C., 2012. Hepsin in the diagnosis of prostate cancer. Minerva Urol. Nefrol., 64(2):143\u2013148.","journal-title":"Minerva Urol. Nefrol."},{"issue":"4","key":"3567_CR178","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0090-4295(01)01311-5","volume":"58","author":"JK Parsons","year":"2001","unstructured":"Parsons, J.K., Gage, W.R., Nelson, W.G., et al., 2001. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology, 58(4):619\u2013624. [doi:10.1016\/S0090-4295(01)01311-5]","journal-title":"Urology"},{"issue":"30","key":"3567_CR179","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1038\/sj.onc.1209695","volume":"25","author":"O Pasder","year":"2006","unstructured":"Pasder, O., Shpungin, S., Salem, Y., et al., 2006. Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene, 25(30):4194\u20134206. [doi:10.1038\/sj.onc.1209695]","journal-title":"Oncogene"},{"issue":"1","key":"3567_CR180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1677\/erc.1.00795","volume":"12","author":"DM Peehl","year":"2005","unstructured":"Peehl, D.M., 2005. Primary cell cultures as models of prostate cancer development. Endocrine-Related Cancer, 12(1):19\u201347. [doi:10.1677\/erc.1.00795]","journal-title":"Endocrine-Related Cancer"},{"issue":"2","key":"3567_CR181","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.pcan.4500871","volume":"9","author":"MC Perttu","year":"2006","unstructured":"Perttu, M.C., Martikainen, P.M., Huhtala, H.S., et al., 2006. Altered levels of Smad2 and Smad4 are associated with human prostate carcinogenesis. Prostate Cancer Prostatic Dis., 9(2):185\u2013189. [doi:10.1038\/sj.pcan.4500871]","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"12","key":"3567_CR182","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak, M., 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer, 8(12):915\u2013928. [doi:10.1038\/nrc2536]","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"3567_CR183","first-page":"95","volume":"4","author":"G Pourmand","year":"2007","unstructured":"Pourmand, G., Ziaee, A.A., Abedi, A.R., et al., 2007. Role of PTEN gene in progression of prostate cancer. Urol. Oncol., 4(2):95\u2013100.","journal-title":"Urol. Oncol."},{"issue":"5","key":"3567_CR184","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0090-4295(00)00776-7","volume":"56","author":"MJ Putzi","year":"2000","unstructured":"Putzi, M.J., de Marzo, A.M., 2000. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology, 56(5):828\u2013832. [doi:10.1016\/S0090-4295(00)00776-7]","journal-title":"Urology"},{"issue":"5A","key":"3567_CR185","first-page":"3917","volume":"23","author":"L Qi","year":"2003","unstructured":"Qi, L., Robinson, W.A., Brady, B.M., et al., 2003. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res., 23(5A):3917\u20133922.","journal-title":"Anticancer Res."},{"issue":"1-2","key":"3567_CR186","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-013-1576-z","volume":"377","author":"F Qu","year":"2013","unstructured":"Qu, F., Cui, X., Hong, Y., et al., 2013. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol. Cell. Biochem., 377(1-2):121\u2013130. [doi:10.1007\/s11010-013-1576-z]","journal-title":"Mol. Cell. Biochem."},{"issue":"5","key":"3567_CR187","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0090-4295(02)01958-1","volume":"60","author":"R Raaijmakers","year":"2002","unstructured":"Raaijmakers, R., Kirkels, W.J., Roobol, M.J., et al., 2002. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology, 60(5):826\u2013830. [doi:10.1016\/S0090-4295(02)01958-1]","journal-title":"Urology"},{"issue":"5","key":"3567_CR188","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.eururo.2007.04.037","volume":"52","author":"R Raaijmakers","year":"2007","unstructured":"Raaijmakers, R., de Vries, S.H., Blijenberg, B.G., et al., 2007. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng\/ml. Eur. Urol., 52(5):1358\u20131364. [doi:10.1016\/j.eururo.2007.04.037]","journal-title":"Eur. Urol."},{"issue":"S2","key":"3567_CR189","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1038\/sj.bjp.0706635","volume":"147","author":"AR Reynolds","year":"2006","unstructured":"Reynolds, A.R., Kyprianou, N., 2006. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Brit. J. Pharmacol., 147(S2):S144\u2013S152. [doi:10.1038\/sj.bjp.0706635]","journal-title":"Brit. J. Pharmacol."},{"issue":"3","key":"3567_CR190","first-page":"10","volume":"43","author":"JM Rhea","year":"2011","unstructured":"Rhea, J.M., Molinaro, R.J., 2011. Cancer biomarkers: surviving the journey from bench to bedside. Med. Lab. Obs., 43(3):10\u201318.","journal-title":"Med. Lab. Obs."},{"issue":"5","key":"3567_CR191","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1096\/fj.07-9526com","volume":"22","author":"WA Ricke","year":"2008","unstructured":"Ricke, W.A., McPherson, S.J., Bianco, J.J., et al., 2008. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J., 22(5):1512\u20131520. [doi:10.1096\/fj.07-9526com]","journal-title":"FASEB J."},{"issue":"3","key":"3567_CR192","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2125.1997.t01-1-00583.x","volume":"44","author":"P Rolan","year":"1997","unstructured":"Rolan, P., 1997. The contribution of clinical pharmacology surrogates and models to drug development-a critical appraisal. Brit. J. Clin. Pharmacol., 44(3):219\u2013225. [doi:10.1046\/j.1365-2125.1997.t01-1-00583.x]","journal-title":"Brit. J. Clin. Pharmacol."},{"issue":"3","key":"3567_CR193","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/carcin\/bgp217","volume":"31","author":"D Romero","year":"2010","unstructured":"Romero, D., Terzic, A., Conley, B.A., et al., 2010. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis, 31(3):359\u2013366. [doi:10.1093\/carcin\/bgp217]","journal-title":"Carcinogenesis"},{"issue":"13","key":"3567_CR194","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.287.13.1662","volume":"287","author":"MA Rubin","year":"2002","unstructured":"Rubin, M.A., Zhou, M., Dhanasekaran, S.M., et al., 2002. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287(13):1662\u20131670. [doi:10.1001\/jama.287.13.1662]","journal-title":"JAMA"},{"issue":"2","key":"3567_CR195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1097-0045(19981001)37:2<84::AID-PROS4>3.0.CO;2-L","volume":"37","author":"C Saez","year":"1998","unstructured":"Saez, C., Gonzalez-Baena, A.C., Japon, M.A., et al., 1998. Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-\u03b2 receptor expression. Prostate, 37(2):84\u201390.","journal-title":"Prostate"},{"issue":"3","key":"3567_CR196","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","volume":"133","author":"L Salmena","year":"2008","unstructured":"Salmena, L., Carracedo, A., Pandolfi, P.P., 2008. Tenets of PTEN tumor suppression. Cell, 133(3):403\u2013414. [doi:10.1016\/j.cell.2008.04.013]","journal-title":"Cell"},{"issue":"2","key":"3567_CR197","first-page":"104","volume":"28","author":"H Samaratunga","year":"2006","unstructured":"Samaratunga, H., Gardiner, R.A., Yaxley, J., et al., 2006. Atypical prostatic glandular proliferations on needle biopsy: diagnostic implications, use of immunohistochemistry, and clinical significance. Anal. Quant. Cytol. Histol., 28(2):104\u2013110.","journal-title":"Anal. Quant. Cytol. Histol."},{"issue":"15","key":"3567_CR198","first-page":"5703","volume":"61","author":"M Schindl","year":"2001","unstructured":"Schindl, M., Oberhuber, G., Obermair, A., et al., 2001. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res., 61(15):5703\u20135706.","journal-title":"Cancer Res."},{"issue":"2","key":"3567_CR199","first-page":"779","volume":"9","author":"M Schindl","year":"2003","unstructured":"Schindl, M., Schoppmann, S.F., Strobel, T., et al., 2003. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res., 9(2):779\u2013785.","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"3567_CR200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eeus.2005.11.003","volume":"4","author":"FH Schr\u00f6der","year":"2006","unstructured":"Schr\u00f6der, F.H., Gosselaar, C., Roemeling, S., et al., 2006. PSA and the detection of prostate cancer after 2005. Part I. EAU-EBU Update Series, 4(1):2\u201312.","journal-title":"Part I. EAU-EBU Update Series"},{"issue":"1","key":"3567_CR201","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","volume":"60","author":"KS Sfanos","year":"2012","unstructured":"Sfanos, K.S., de Marzo, A.M., 2012. Prostate cancer and inflammation: the evidence. Histopathology, 60(1):199\u2013215. [doi:10.1111\/j.1365-2559.2011.04033.x]","journal-title":"Histopathology"},{"issue":"2","key":"3567_CR202","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1083\/jcb.200307151","volume":"164","author":"W Shi","year":"2004","unstructured":"Shi, W., Sun, C., He, B., et al., 2004. GADD34-PP1c recruited by Smad7 dephosphorylates TGF\u03b2 type I receptor. J. Cell Biol., 164(2):291\u2013300. [doi:10.1083\/jcb.200307151]","journal-title":"J. Cell Biol."},{"issue":"1","key":"3567_CR203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ucl.2009.11.004","volume":"37","author":"A Shteynshlyuger","year":"2010","unstructured":"Shteynshlyuger, A., Andriole, G.L., 2010. Prostate cancer: to screen or not to screen? Urol. Clin. N. Am., 37(1):1\u20139. [doi:10.1016\/j.ucl.2009.11.004]","journal-title":"Urol. Clin. N. Am."},{"issue":"7","key":"3567_CR204","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ejca.2008.02.051","volume":"44","author":"PB Singh","year":"2008","unstructured":"Singh, P.B., Matanhelia, S.S., Martin, F.L., 2008. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur. J. Cancer, 44(7):928\u2013936. [doi:10.1016\/j.ejca.2008.02.051]","journal-title":"Eur. J. Cancer"},{"key":"3567_CR205","unstructured":"Smith, R.A., Mettlin, C.J., Eyre, H., 2003. Cancer screening and early detection. In: Kufe, D.W., Pollock, R.E., Weichselbaum, R.R. (Eds.), Holland-Frei Cancer Medicine. BC Decker, Canada."},{"issue":"9","key":"3567_CR206","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/bjc.2012.436","volume":"107","author":"A Som","year":"2012","unstructured":"Som, A., Tu, S.M., Liu, J., et al., 2012. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Brit. J. Cancer, 107(9):1547\u20131553. [doi:10.1038\/bjc.2012.436]","journal-title":"Brit. J. Cancer"},{"issue":"2","key":"3567_CR207","first-page":"305","volume":"29","author":"N Soulitzis","year":"2006","unstructured":"Soulitzis, N., Karyotis, I., Delakas, D., et al., 2006. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. J. Oncol., 29(2):305\u2013314.","journal-title":"Int. J. Oncol."},{"issue":"5","key":"3567_CR208","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ng0509-509","volume":"41","author":"JA Squire","year":"2009","unstructured":"Squire, J.A., 2009. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat. Genet., 41(5):509\u2013510. [doi:10.1038\/ng0509-509]","journal-title":"Nat. Genet."},{"issue":"1","key":"3567_CR209","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-5347(05)65392-X","volume":"167","author":"TA Stamey","year":"2002","unstructured":"Stamey, T.A., Johnstone, I.M., McNeal, J.E., et al., 2002. Preoperative serum prostate specific antigen levels between 2 and 22 ng\/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng\/ml. J. Urol., 167(1):103\u2013111. [doi:10.1016\/S0022-5347(05)65392-X]","journal-title":"J. Urol."},{"issue":"15","key":"3567_CR210","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2004.10.105","volume":"22","author":"P Stattin","year":"2004","unstructured":"Stattin, P., Rinaldi, S., Biessy, C., et al., 2004. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J. Clin. Oncol., 22(15):3104\u20133112. [doi:10.1200\/jco.2004.10.105]","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"3567_CR211","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1373\/clinchem.2006.074963","volume":"53","author":"T Steuber","year":"2007","unstructured":"Steuber, T., Vickers, A.J., Serio, A.M., et al., 2007. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin. Chem., 53(2):233\u2013240. [doi:10.1373\/clinchem.2006.074963]","journal-title":"Clin. Chem."},{"issue":"6","key":"3567_CR212","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1541-7786.MCR-10-0573","volume":"9","author":"J Szczyrba","year":"2011","unstructured":"Szczyrba, J., Nolte, E., Wach, S., et al., 2011. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol. Cancer Res., 9(6):791\u2013800. [doi:10.1158\/1541-7786.mcr-10-0573]","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"3567_CR213","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbrc.2013.01.051","volume":"431","author":"J Taira","year":"2013","unstructured":"Taira, J., Higashimoto, Y., 2013. Caveolin-1 interacts with protein phosphatase 5 and modulates its activity in prostate cancer cells. Biochem. Biophys. Res. Commun., 431(4):724\u2013728. [doi:10.1016\/j.bbrc.2013.01.051]","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"3567_CR214","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/pcan.2011.48","volume":"15","author":"J Teishima","year":"2012","unstructured":"Teishima, J., Shoji, K., Hayashi, T., et al., 2012. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis., 15(1):8\u201314. [doi:10.1038\/pcan.2011.48]","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"3567_CR215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","volume":"139","author":"M Thalgott","year":"2013","unstructured":"Thalgott, M., Rack, B., Maurer, T., et al., 2013. Detection of circulating tumor cells in different stages of prostate cancer. J. Cancer Res. Clin. Oncol., 139(5):755\u2013763. [doi:10.1007\/s00432-013-1377-5]","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"3567_CR216","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.maturitas.2011.04.012","volume":"69","author":"E Thara","year":"2011","unstructured":"Thara, E., Dorff, T.B., Pinski, J.K., et al., 2011. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas, 69(4):296\u2013303. [doi:10.1016\/j.maturitas.2011.04.012]","journal-title":"Maturitas"},{"issue":"5748","key":"3567_CR217","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S.A., Rhodes, D.R., Perner, S., et al., 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748):644\u2013648. [doi:10.1126\/science.1117679]","journal-title":"Science"},{"issue":"3","key":"3567_CR218","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.urology.2009.04.032","volume":"75","author":"EG Treat","year":"2010","unstructured":"Treat, E.G., Heaphy, C.M., Massie, L.W., et al., 2010. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology, 75(3):724\u2013729. [doi:10.1016\/j.urology.2009.04.032]","journal-title":"Urology"},{"issue":"2","key":"3567_CR219","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00240-003-0383-5","volume":"32","author":"L Trojan","year":"2004","unstructured":"Trojan, L., Thomas, D., Knoll, T., et al., 2004. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol. Res., 32(2):97\u2013103. [doi:10.1007\/s00240-003-0383-5]","journal-title":"Urol. Res."},{"issue":"3","key":"3567_CR220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1476-5586(03)80058-1","volume":"5","author":"WH Tu","year":"2003","unstructured":"Tu, W.H., Thomas, T.Z., Masumori, N., et al., 2003. The loss of TGF-\u03b2 signaling promotes prostate cancer metastasis. Neoplasia, 5(3):267\u2013277.","journal-title":"Neoplasia"},{"issue":"2","key":"3567_CR221","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0027-9684(15)30264-9","volume":"103","author":"BJ Turner","year":"2011","unstructured":"Turner, B.J., Mavandadi, S., Weiner, M.G., 2011. Association of black race with follow-up of an abnormal prostate-specific antigen test. J. Natl. Med. Assoc., 103(2):150\u2013157.","journal-title":"J. Natl. Med. Assoc."},{"key":"3567_CR222","doi-asserted-by":"crossref","DOI":"10.1016\/S1476-5586(03)80058-1","volume-title":"Provenge. US Food and Drug Administration","author":"US FoodDrug Administration","year":"2010","unstructured":"US Food and Drug Administration, 2010. Provenge. US Food and Drug Administration. Available from http:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeCeTherapy Products\/ApprovedProducts\/ucm210012.htm [Accessed on Feb. 28, 2013]."},{"issue":"2","key":"3567_CR223","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0027-9684(15)30264-9","volume":"9","author":"TG Vandenboom Ii","year":"2008","unstructured":"Vandenboom Ii, T.G., Li, Y., Philip, P.A., et al., 2008. MicroRNA and cancer: tiny molecules with major implications. Curr. Genomics, 9(2):97\u2013109. [doi:10.2174\/138920208784139555]","journal-title":"Curr. Genomics"},{"issue":"1","key":"3567_CR224","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/pros.21043","volume":"70","author":"DJ Vander Griend","year":"2010","unstructured":"Vander Griend, D.J., D\u2019Antonio, J., Gurel, B., et al., 2010. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate, 70(1):90\u201399. [doi:10.1002\/pros.21043]","journal-title":"Prostate"},{"issue":"11","key":"3567_CR225","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1593\/neo.08922","volume":"10","author":"S Varambally","year":"2008","unstructured":"Varambally, S., Laxman, B., Mehra, R., et al., 2008. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia, 10(11):1285\u20131294.","journal-title":"Neoplasia"},{"issue":"10","key":"3567_CR226","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/pros.21326","volume":"71","author":"BT Vo","year":"2011","unstructured":"Vo, B.T., Khan, S.A., 2011. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate, 71(10):1084\u20131096. [doi:10.1002\/pros.21326]","journal-title":"Prostate"},{"issue":"12","key":"3567_CR227","doi-asserted-by":"crossref","first-page":"e46888","DOI":"10.1371\/journal.pone.0046888","volume":"7","author":"H Wang","year":"2012","unstructured":"Wang, H., Fan, L., Wei, J., et al., 2012. Akt mediates metastasis-associated gene 1 (MTA1) regulating the expression of E-cadherin and promoting the invasiveness of prostate cancer cells. PLoS ONE, 7(12):e46888. [doi:10.1371\/journal.pone.0046888]","journal-title":"PLoS ONE"},{"issue":"8","key":"3567_CR228","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1593\/neo.08450","volume":"10","author":"J Wang","year":"2008","unstructured":"Wang, J., Yu, W., Cai, Y., et al., 2008. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia, 10(8):847\u2013856.","journal-title":"Neoplasia"},{"issue":"13","key":"3567_CR229","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/pros.20992","volume":"69","author":"W Wang","year":"2009","unstructured":"Wang, W., Bergh, A., Damber, J.E., 2009. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate, 69(13):1378\u20131386. [doi:10.1002\/pros.20992]","journal-title":"Prostate"},{"issue":"4","key":"3567_CR230","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/pros.10083","volume":"51","author":"P Wikstrom","year":"2002","unstructured":"Wikstrom, P., Lissbrant, I.F., Stattin, P., et al., 2002. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 51(4):268\u2013275. [doi:10.1002\/pros.10083]","journal-title":"Prostate"},{"key":"3567_CR231","volume-title":"AHRQ Comparative Effectiveness Reviews","author":"TJ Wilt","year":"2008","unstructured":"Wilt, T.J., Shamliyan, T., Taylor, B., et al., 2008. Comparative effectiveness of therapies for clinically localized prostate cancer. In: Agency for Healthcare Research and Quality (Ed.), AHRQ Comparative Effectiveness Reviews. Rockville, United States of America."},{"issue":"2","key":"3567_CR232","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.juro.2007.09.073","volume":"179","author":"K Woodson","year":"2008","unstructured":"Woodson, K., O\u2019Reilly, K.J., Hanson, J.C., et al., 2008. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol., 179(2):508\u2013511, Discussion 511-502. [doi:10.1016\/j.juro.2007.09.073]","journal-title":"J. Urol."},{"issue":"7","key":"3567_CR233","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/carcin\/bgm050","volume":"28","author":"Z Wu","year":"2007","unstructured":"Wu, Z., McRoberts, K.S., Theodorescu, D., 2007. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis, 28(7):1393\u20131400. [doi:10.1093\/carcin\/bgm050]","journal-title":"Carcinogenesis"},{"issue":"6","key":"3567_CR234","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pros.22600","volume":"73","author":"Z Wu","year":"2012","unstructured":"Wu, Z., He, B., He, J., et al., 2012. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate, 73(6):596\u2013604. [doi:10.1002\/pros.22600]","journal-title":"Prostate"},{"issue":"13","key":"3567_CR235","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/pros.21355","volume":"71","author":"T Xu","year":"2011","unstructured":"Xu, T., He, K., Wang, L., et al., 2011. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate, 71(13):1390\u20131400. [doi:10.1002\/pros.21355]","journal-title":"Prostate"},{"issue":"27","key":"3567_CR236","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/oxfordjournals.jncimonographs.a024245","volume":"2000","author":"JD Yager","year":"2000","unstructured":"Yager, J.D., 2000. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr., 2000(27):67\u201373.","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"3","key":"3567_CR237","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s13277-011-0154-9","volume":"32","author":"F Yaman Agaoglu","year":"2011","unstructured":"Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., et al., 2011. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol., 32(3):583\u2013588. [doi:10.1007\/s13277-011-0154-9]","journal-title":"Tumour Biol."},{"issue":"4","key":"3567_CR238","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.onc.1210663","volume":"27","author":"F Yang","year":"2008","unstructured":"Yang, F., Strand, D.W., Rowley, D.R., 2008. Fibroblast growth factor-2 mediates transforming growth factor-\u03b2 action in prostate cancer reactive stroma. Oncogene, 27(4):450\u2013459. [doi:10.1038\/sj.onc.1210663]","journal-title":"Oncogene"},{"issue":"1","key":"3567_CR239","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2867-5-8","volume":"5","author":"Q Yang","year":"2005","unstructured":"Yang, Q., Fung, K.M., Day, W.V., et al., 2005. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int., 5(1):8. [doi:10.1186\/1475-2867-5-8]","journal-title":"Cancer Cell Int."},{"issue":"41","key":"3567_CR240","doi-asserted-by":"crossref","first-page":"36152","DOI":"10.1074\/jbc.M111.265124","volume":"286","author":"X Yang","year":"2011","unstructured":"Yang, X., Guo, Z., Sun, F., et al., 2011. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J. Biol. Chem., 286(41):36152\u201336160. [doi:10.1074\/jbc.M111.265124]","journal-title":"J. Biol. Chem."},{"issue":"1","key":"3567_CR241","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13167-011-0138-2","volume":"3","author":"TA Yap","year":"2012","unstructured":"Yap, T.A., Swanton, C., de Bono, J.S., 2012. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J., 3(1):3. [doi:10.1007\/s13167-011-0138-2]","journal-title":"EPMA J."},{"issue":"10","key":"3567_CR242","first-page":"1129","volume":"22","author":"L Ye","year":"2007a","unstructured":"Ye, L., Lewis-Russell, J.M., Kyanaston, H.G., et al., 2007a. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol. Histopathol., 22(10):1129\u20131147.","journal-title":"Histol. Histopathol."},{"issue":"3Pt1","key":"3567_CR243","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.juro.2007.05.003","volume":"178","author":"L Ye","year":"2007b","unstructured":"Ye, L., Lewis-Russell, J.M., Kynaston, H., et al., 2007b. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J. Urol., 178(3 Pt 1):1086\u20131091. [doi:10.1016\/j.juro.2007.05.003]","journal-title":"J. Urol."},{"issue":"10","key":"3567_CR244","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1158\/1541-7786.MCR-08-0171","volume":"6","author":"L Ye","year":"2008","unstructured":"Ye, L., Kynaston, H., Jiang, W.G., 2008. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol. Cancer Res., 6(10):1594\u20131606. [doi:10.1158\/1541-7786.mcr-08-0171]","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"3567_CR245","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1016\/j.juro.2009.01.098","volume":"181","author":"L Ye","year":"2009","unstructured":"Ye, L., Kynaston, H., Jiang, W.G., 2009. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J. Urol., 181(6):2749\u20132759. [doi:10.1016\/j.juro.2009.01.098]","journal-title":"J. Urol."},{"issue":"7","key":"3567_CR246","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/1087057112444445","volume":"17","author":"HY Yoon","year":"2012","unstructured":"Yoon, H.Y., Kim, S.K., Kim, Y.W., et al., 2012. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J. Biomol. Screen., 17(7):987\u2013992. [doi:10.1177\/1087057112444445]","journal-title":"J. Biomol. Screen."},{"issue":"12","key":"3567_CR247","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/modpathol.2008.94","volume":"21","author":"HF Yuen","year":"2008","unstructured":"Yuen, H.F., Chan, Y.P., Cheung, W.L., et al., 2008. The prognostic significance of BMP-6 signaling in prostate cancer. Modern Pathol., 21(12):1436\u20131443. [doi:10.1038\/modpathol.2008.94]","journal-title":"Modern Pathol."},{"issue":"4","key":"3567_CR248","doi-asserted-by":"crossref","first-page":"E889","DOI":"10.1016\/j.juro.2012.02.2380","volume":"187","author":"V Yutkin","year":"2012","unstructured":"Yutkin, V., Al-Zahrani, A., Williams, A., et al., 2012. Pca3 test as an adjunct in diagnosis of prostate cancer. J. Urol., 187(4):E889\u2013E889.","journal-title":"J. Urol."},{"issue":"16","key":"3567_CR249","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/pros.21215","volume":"70","author":"Z Zhao","year":"2010","unstructured":"Zhao, Z., Zeng, G., Zhong, W., 2010. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. Prostate, 70(16):1788\u20131798. [doi:10.1002\/pros.21215]","journal-title":"Prostate"},{"issue":"3","key":"3567_CR250","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/pros.21428","volume":"72","author":"Z Zhao","year":"2012","unstructured":"Zhao, Z., Ma, W., Zeng, G., et al., 2012. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy. Prostate, 72(3):270\u2013279. [doi:10.1002\/pros.21428]","journal-title":"Prostate"},{"issue":"11","key":"3567_CR251","doi-asserted-by":"crossref","first-page":"e48889","DOI":"10.1371\/journal.pone.0048889","volume":"7","author":"X Zhou","year":"2012","unstructured":"Zhou, X., Mao, J., Ai, J., et al., 2012. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS ONE, 7(11):e48889. [doi:10.1371\/journal.pone.0048889]","journal-title":"PLoS ONE"},{"issue":"4","key":"3567_CR252","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","volume":"15","author":"ML Zhu","year":"2008","unstructured":"Zhu, M.L., Kyprianou, N., 2008. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocrine-Related Cancer, 15(4):841\u2013849. [doi:10.1677\/erc-08-0084]","journal-title":"Endocrine-Related Cancer"}],"container-title":["Journal of Zhejiang University SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1300106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1631\/jzus.B1300106\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1300106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:38:52Z","timestamp":1746099532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1631\/jzus.B1300106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":252,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1300106","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}